Smartlab Europe

Press Releases

Pfizer and BioNTech Receive First U.S. Authorization for Emergency Use of COVID-19 Vaccine in Adolescents

Pfizer Inc. and BioNTech SE announced today that the U.S. FDA has expanded the Emergency Use Authorization (EUA) for their COVID-19 vaccine to include individuals 12 to 15 years of age. This is the first COVID-19 vaccine authorized in...

GSK and Vir Biotechnology Announce the Start of the EMA Rolling Review of VIR-7831 for the Early Treatment of COVID-19

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced that the EMA has started a rolling review of data on sotrovimab, an investigational dual-action SARS-CoV-2 monoclonal antibody, for the treatment of adults and adolescents (aged 12 years and over and weighing...

Vectura and Inspira Pharmaceuticals Sign Agreement to Develop Potential Inhaled Treatment for COVID-19

Vectura Group plc, an industry leading inhalation CDMO, and Inspira Pharmaceuticals Limited, a new UK-based company focused on developing therapies for respiratory and infectious diseases, announced an agreement to develop an inhaled formulation of Inspira’s lead drug candidate for...

Cryoport and LabConnectPartner to Provide Support for Innovative Triumvira Cell and Gene Therapy Clinical Trial

LabConnect, Inc. and Cryoport, Inc. announced a partnership to provide comprehensive logistics support for an upcoming Phase I/II clinical trial sponsored by Triumvira Immunologics Inc., a privately held biopharmaceutical company developing a novel platform for engineering T cells to...

Moderna Announces Emergency Use Listing Granted by the World Health Organization for its COVID-19 Vaccine

Moderna, Inc. , a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced that the World Health Organization (WHO) has issued Emergency Use Listing (EUL) for its COVID-19 vaccine to prevent COVID-19 in individuals 18 years of age...

Moderna Announces Additional Investments to Increase Global Supply for COVID-19 Vaccine to up to 3 Billion Doses in 2022

Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, announced it is making new funding commitments to increase supply at its owned and partnered manufacturing facilities, which it expects will increase global 2022 capacity to up...

Lonza and Moderna Enter New Agreement to Double Drug Substance Production for COVID-19 Vaccine in Visp

Lonza announced the expansion of its collaboration with Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, to manufacture the drug substance for the COVID-19 Vaccine Moderna. The expanded collaboration provides for the installation of three additional drug...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Must read

Translate »